Clinical Trials Sponsored by Imsmed Incorporated

Total 1369 results

Insmed Incorporated

Recruiting

A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants (INS1007)

Healthy Participants

United States
Insmed Incorporated

Recruiting

A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) (BiRCh)

Chronic Rhinosinusitis Without Nasal Polyps

United States, Australia, Argentina, Canada
Insmed Incorporated

Recruiting

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Argentina, Brazil, Germany, Italy, Malaysia, Philippines, Spain, United Kingdom, Serbia, Japan, United States, Mexico
Insmed Incorporated

Recruiting

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Pulmonary Hypertension | Interstitial Lung Disease

Belgium, Germany, Spain, Italy, Argentina, Australia, United Kingdom
Insmed Incorporated

Recruiting

Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex (ENCORE)

Mycobacterium Infections, Nontuberculous

Belgium, New Zealand, United Kingdom, United States, Argentina, Australia, Austria, Canada, Chile, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Spain, Taiwan, Turkey, Portugal
Insmed Incorporated

Terminated

A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United States
Insmed Incorporated

Completed

A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants

Healthy Volunteers

United States
Insmed Incorporated

Completed

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

Hepatic Impairment

United States
Insmed Incorporated

Completed

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants

Healthy Volunteers

United States
Insmed Incorporated

Completed

Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex (ARISE)

Mycobacterium Infections, Nontuberculous

United States, Argentina, Australia, Austria, Canada, Chile, Denmark, Germany, Israel, Italy, Korea, Republic of, New Zealand, Spain, Taiwan
Insmed Incorporated

Completed

A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment

Renal Impairment

United States
Insmed Incorporated

Completed

A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants

Healthy Volunteer

United States
Insmed Incorporated

Completed

Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase

Cystic Fibrosis

Poland, Ukraine, Serbia, Belgium, Hungary, Slovakia, North Macedonia
Insmed Incorporated

Completed

Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection

Cystic Fibrosis

France, Poland, United Kingdom, Germany, Spain, Belgium, Bulgaria, Serbia, Denmark, Greece, Netherlands, Hungary, Ireland, Slovakia, Canada, Italy, Austria
Insmed Incorporated

Completed

Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone (CONVERT)

Mycobacterium Infections, Nontuberculous
Insmed Incorporated

Completed

Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212

NTM Lung Infection Due to MAC
Insmed Incorporated

Completed

Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.

Bronchiectasis

United States, United Kingdom, Bulgaria, India, Serbia, Ukraine, Greece, Hungary, Poland
Insmed Incorporated

Withdrawn

Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa

Cystic Fibrosis
Insmed Incorporated

Completed

IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome

Laron Syndrome | Growth Hormone Insensitivity Syndrome (GHIS)

United States, Argentina, Australia, Brazil, China, Egypt, Germany, Israel, Italy, Norway, Peru, Slovakia, Turkey, United Kingdom
Insmed Incorporated

Terminated

Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome

Noonan Syndrome

United States
Insmed Incorporated

Recruiting

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, Spain, Argentina, Australia, Belgium, Brazil, Germany, Italy, Japan, Malaysia, Mexico, Philippines, Switzerland, United Kingdom, Serbia, Austria, Denmark
Insmed Incorporated

Active, not recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis (ASPEN)

Non-Cystic Fibrosis Bronchiectasis

New Zealand, United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Malaysia, Mexico, Nethe... and more
Insmed Incorporated

Available

An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis

Non-Cystic Fibrosis Bronchiectasis
Insmed Incorporated

Completed

A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants

Healthy Volunteers

United States
Insmed Incorporated

Completed

A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants

Healthy Volunteers

United States
Insmed Incorporated

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

Cystic Fibrosis

United States
Insmed Incorporated

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

Healthy Volunteers

United States
Insmed Incorporated

Completed

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

Non-Cystic Fibrosis Bronchiectasis

United States, Spain, Korea, Republic of, Australia, Denmark, United Kingdom, Italy, Belgium, Singapore, Bulgaria, Germany, Netherlands, New Zealand, Poland
Insmed Incorporated

Completed

A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants

Healthy Volunteers

United States
Insmed Incorporated

Completed

A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

Pulmonary Hypertension

Belgium, Germany, Spain, Argentina, Australia, Italy, United Kingdom
Insmed Incorporated

Completed

Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa

Cystic Fibrosis
Insmed Incorporated

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants

Healthy Volunteers

United States
Insmed Incorporated

Completed

A Study to Investigate Lung Deposition of Inhaled Amikacin-loaded Liposomes in Healthy Male Participants

Healthy Volunteers
Insmed Incorporated

Completed

Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)

Cystic Fibrosis

Poland, Ukraine, Serbia, Belgium, Hungary, Slovakia, North Macedonia
Insmed Incorporated

Completed

Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections

Pseudomonas Aeruginosa Infection

France, Poland, United Kingdom, Germany, Spain, Belgium, Bulgaria, Denmark, Greece, Canada, Netherlands, Hungary, Italy, Ireland, Sweden, Slovakia, Austria, Serbia
Insmed Incorporated

Completed

Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa

Cystic Fibrosis

United States
Insmed Incorporated

Completed

Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung

Osteosarcoma Metastatic

United States
Insmed Incorporated
Muscular Dystrophy Association

Completed

Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1

Myotonic Dystrophy Type 1

United States
University of Calgary
Insmed Incorporated; Trudell Medical

Recruiting

Development of a Canadian Bronchiectasis and NTM Database

Bronchiectasis | Non-Tuberculous Mycobacterial Pneumonia

Canada
University of Dundee
NHS Tayside; Insmed Incorporated

Completed

STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19 (STOP-COVID19)

Covid19

United Kingdom
University of California, San Francisco
Insmed Incorporated

Terminated

Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer

Prostate Cancer

United States
Insmed Incorporated
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria

Mycobacterium Infections, Nontuberculous

United States, Canada
University of Rochester
National Institute of Neurological Disorders and Stroke (NINDS); Imsmed Incorporated

Completed

Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)

Myotonic Dystrophy

United States
Cook Group Incorporated
MED Institute, Incorporated; Cook Biotech Incorporated

Completed

Inguinal Hernia Study Using Biodesign IHM

Inguinal Hernia

United States
Cook Group Incorporated
MED Institute, Incorporated; Cook Biotech Incorporated

Completed

Evaluation of Surgisis Gold Graft for Incision Reinforcement After Open Bariatric Surgery

Obesity | Hernia

United States
ResMed
ResMed Foundation

Terminated

Cardiovascular Improvements With MV ASV Therapy in Heart Failure (CAT-HF)

Acute Decompensated Heart Failure | Sleep Disordered Breathing

United States, Germany
Cook Research Incorporated

Recruiting

Post Market Clinical Study - Evolution® Esophageal Stent Systems, Europe: Fully and Partially Covered

Esophageal Diseases

Germany, Spain, United Kingdom
Cook Research Incorporated

Recruiting

Zenith® Fenestrated+ Clinical Study

Aortic Aneurysm, Abdominal | Juxtarenal Aortic Aneurysm | Extent IV Thoracoabdominal | Pararenal Aneurysm

United States
Cook Research Incorporated

Recruiting

Biodesign® Otologic Repair Graft

Tympanic Membrane Perforation | Eardrum Perforation

United States
Cook Research Incorporated

Completed

Comparing a Direct Versus an Indirect Approach to Measuring the Portalsytemic Pressure Gradients

Liver Cirrhosis

Belgium, Spain, Netherlands

Clinical Trials Sponsored by Imsmed Incorporated

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations